EBS Quote, Financials, Valuation and Earnings

Cara Therapeutics has a net margin of -16.54% compared to Emergent BioSolutions's net margin of -527.77%. Emergent BioSolutions's return on equity of -35.42% beat Cara Therapeutics's return on equity of -374.56%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 194.76%. On the other hand Cara Therapeutics has an analysts' consensus of $12.00 which suggests that it could grow by 116.22%. Given that Emergent BioSolutions has higher upside potential than Cara Therapeutics, analysts believe Emergent BioSolutions is more attractive than Cara Therapeutics.

Emergent BioSolutions has a beta of 2.141, which suggesting that the stock is 114.124% more volatile than S&P 500. In comparison Cara Therapeutics has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.556%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Cara Therapeutics pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than Cara Therapeutics quarterly revenues of $1.5M. Emergent BioSolutions's net income of -$31.3M is lower than Cara Therapeutics's net income of -$7.7M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Cara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.24x versus 3.55x for Cara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ekso Bionics Holdings has a net margin of -16.54% compared to Emergent BioSolutions's net margin of -67.05%. Emergent BioSolutions's return on equity of -35.42% beat Ekso Bionics Holdings's return on equity of -85.45%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 194.76%. On the other hand Ekso Bionics Holdings has an analysts' consensus of $9.00 which suggests that it could grow by 1222.75%. Given that Ekso Bionics Holdings has higher upside potential than Emergent BioSolutions, analysts believe Ekso Bionics Holdings is more attractive than Emergent BioSolutions.

Emergent BioSolutions has a beta of 2.141, which suggesting that the stock is 114.124% more volatile than S&P 500. In comparison Ekso Bionics Holdings has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.141%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ekso Bionics Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Ekso Bionics Holdings pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than Ekso Bionics Holdings quarterly revenues of $5.1M. Emergent BioSolutions's net income of -$31.3M is lower than Ekso Bionics Holdings's net income of -$3.4M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Ekso Bionics Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.24x versus 0.43x for Ekso Bionics Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix has a net margin of -16.54% compared to Emergent BioSolutions's net margin of -283.27%. Emergent BioSolutions's return on equity of -35.42% beat Ocular Therapeutix's return on equity of -62.66%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 194.76%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 131.18%. Given that Emergent BioSolutions has higher upside potential than Ocular Therapeutix, analysts believe Emergent BioSolutions is more attractive than Ocular Therapeutix.

Emergent BioSolutions has a beta of 2.141, which suggesting that the stock is 114.124% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.491, suggesting its more volatile than the S&P 500 by 49.133%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than Ocular Therapeutix quarterly revenues of $17.1M. Emergent BioSolutions's net income of -$31.3M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.24x versus 18.80x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -16.54% compared to Emergent BioSolutions's net margin of 21.57%. Emergent BioSolutions's return on equity of -35.42% beat TG Therapeutics's return on equity of 12.81%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 194.76%. On the other hand TG Therapeutics has an analysts' consensus of $43.00 which suggests that it could grow by 11.95%. Given that Emergent BioSolutions has higher upside potential than TG Therapeutics, analysts believe Emergent BioSolutions is more attractive than TG Therapeutics.

Emergent BioSolutions has a beta of 2.141, which suggesting that the stock is 114.124% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.139, suggesting its more volatile than the S&P 500 by 113.867%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than TG Therapeutics quarterly revenues of $108.2M. Emergent BioSolutions's net income of -$31.3M is lower than TG Therapeutics's net income of $23.3M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 274.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.24x versus 18.29x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.